Zerhouni trumpets new R&D mindset at Sanofi

Sanofi ($SNY) has reorganized its research and development over the past couple of years, and R&D chief Elias Zerhouni offered up some insights about the new mindset at the French drug giant. For example, the company has emphasized a focus on results of clinical programs over the scientific bureaucracy that has been implicated in the industry's lack of R&D productivity. "The project is what matters, not people's titles," Zerhouni said, as quoted by Bloomberg. "The least hierarchical the model is, the better." Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.